High crossreactivity of human T cell responses between Lassa virus lineages
暂无分享,去创建一个
Pardis C Sabeti | Brian C. Ware | Brian C Ware | Dylan Kotliar | K. Gangavarapu | R. Garry | C. Happi | J. C. de la Torre | M. Oldstone | O. Folarin | D. Grant | J. Schieffelin | A. Goba | Mambu Momoh | S. Okogbenin | P. Okokhere | R. Robles-Sikisaka | B. Cubitt | J. Hartnett | Saori Sakabe | B. Sullivan | I. Odia | E. Ogbaini-Emovon | N. Ngo | Luis Branco | Selma D Garcia | John Demby Sandi | P. Eromon | K. Andersen | L. Kanneh | Nhi T. Ngo | Philomena J. Eromon
[1] D. Kranz,et al. T-cell Receptors Engineered De Novo for Peptide Specificity Can Mediate Optimal T-cell Activity without Self Cross-Reactivity , 2019, Cancer Immunology Research.
[2] Lisa E. Wagar,et al. Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children , 2019, Front. Immunol..
[3] P. Lemey,et al. Phylogeography of Lassa Virus in Nigeria , 2019, Journal of Virology.
[4] C. Ihekweazu,et al. A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[5] S. Gilbert,et al. Vaccine platforms for the prevention of Lassa fever , 2019, Immunology Letters.
[6] M. A. Suchard,et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak , 2019, Science.
[7] Mayuko Kimura,et al. Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria , 2018, PLoS neglected tropical diseases.
[8] Catherine A. Freije,et al. Genomic analysis of Lassa virus from the 2018 surge in Nigeria , 2018, The New England journal of medicine.
[9] Brian C. Ware,et al. Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics , 2018, Proceedings of the National Academy of Sciences.
[10] Karthik Gangavarapu,et al. Analysis of CD8+ T cell response during the 2013–2016 Ebola epidemic in West Africa , 2018, Proceedings of the National Academy of Sciences.
[11] B. R. Noack,et al. New Lineage of Lassa Virus, Togo, 2016 , 2018, Emerging infectious diseases.
[12] Donald S. Grant,et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever , 2017, Nature Medicine.
[13] Jay B. Varkey,et al. A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses , 2017, The Journal of infectious diseases.
[14] K. Chandran,et al. Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.
[15] Pardis C Sabeti,et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits , 2016, Nature Communications.
[16] S. Günther,et al. Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever , 2016, PLoS pathogens.
[17] N. Forrester,et al. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage , 2015, Front. Microbiol..
[18] Elizabeth M. Ryan,et al. Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus , 2015, Cell.
[19] L. Moses,et al. Sequence Variability and Geographic Distribution of Lassa Virus, Sierra Leone , 2015, Emerging infectious diseases.
[20] C. Ng,et al. Type I interferon is a therapeutic target for virus-induced lethal vascular damage , 2014, Proceedings of the National Academy of Sciences.
[21] Mark M. Davis,et al. Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.
[22] J. Altman,et al. Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells. , 2012, Journal of immunological methods.
[23] D. Price,et al. A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.
[24] S. Günther,et al. Current Molecular Epidemiology of Lassa Virus in Nigeria , 2010, Journal of Clinical Microbiology.
[25] S. Günther,et al. T Cell-Dependence of Lassa Fever Pathogenesis , 2010, PLoS pathogens.
[26] N. Tordo,et al. Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys , 2009, Journal of Virology.
[27] Bjoern Peters,et al. The CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus Involves the L Antigen: Uncovering New Tricks for an Old Virus , 2007, Journal of Virology.
[28] R. Ahmed,et al. Quantitating the Magnitude of the Lymphocytic Choriomeningitis Virus-Specific CD8 T-Cell Response: It Is Even Bigger than We Thought , 2006, Journal of Virology.
[29] B. Mothé,et al. Development of a New Vaccine for the Prevention of Lassa Fever , 2005, PLoS medicine.
[30] A. Hoerauf,et al. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. , 2004, Virology.
[31] Alessandro Sette,et al. Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. , 2003, Virology.
[32] A. Sette,et al. In Vivo Selection of a Lymphocytic Choriomeningitis Virus Variant That Affects Recognition of the GP33-43 Epitope by H-2Db but Not H-2Kb , 2001, Journal of Virology.
[33] Stuart T. Nichol,et al. Genetic Diversity among Lassa Virus Strains , 2000, Journal of Virology.
[34] L. Hutwagner,et al. Effective Vaccine for Lassa Fever , 2000, Journal of Virology.
[35] A. Hoerauf,et al. Characterization of Human CD4+ T-Cell Clones Recognizing Conserved and Variable Epitopes of the Lassa Virus Nucleoprotein , 2000, Journal of Virology.
[36] C Oseroff,et al. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. , 1998, Virology.
[37] J. Sidney,et al. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. , 1996, Journal of immunology.
[38] L. Hutwagner,et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice , 1995, BMJ.
[39] M. Oldstone,et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes , 1995, Journal of virology.
[40] J. McCormick,et al. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys , 1992, Journal of medical virology.
[41] J. Whitton,et al. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus , 1988, Journal of virology.
[42] S. Fisher-Hoch. Lessons from nosocomial viral haemorrhagic fever outbreaks. , 2005, British medical bulletin.